Seurat Therapeutics Announces Novel Mechanisms from Rat Migraine Model of Intranasal Insulin-like Growth Factor-1

Seurat Therapeutics, Inc. (Seurat) announced today the publication of preclinical studies of its lead product candidate, intranasal insulin-like growth factor-1 (IGF-1), in a rat model of migraine headaches, in the scientific journal Brain Research.